Showing 1 - 20 results of 33 for search 'Ping‐Chih Hsu', query time: 0.09s Refine Results
  1. 1
    Forced Overexpression of Signal Transducer and Activator of Transcription 3 (STAT3) Activates Yes-Associated Protein (YAP) Expression and Increases the Invasion and Proliferation Abilities of Small Cell Lung Cancer (SCLC) Cells

    Forced Overexpression of Signal Transducer and Activator of Transcription 3 (STAT3) Activates Yes-Associated Protein (YAP) Expression and Increases the Invasion and Proliferation A... by Ping-Chih Hsu, Jhy-Ming Li, Cheng-Ta Yang

    Published 2022-07-01
    Get full text
    Article
  2. 2
    The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)

    The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC) by Ping-Chih Hsu, Cheng-Ta Yang, David M. Jablons, Liang You

    Published 2020-05-01
    Get full text
    Article
  3. 3
    The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer

    The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer by Ping-Chih Hsu, Cheng-Ta Yang, David M. Jablons, Liang You

    Published 2018-12-01
    Get full text
    Article
  4. 4
    Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports

    Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case... by Ping-Chih Hsu, Tai-Di Chen, Tsung-Yu Tsai, Cheng-Ta Yang

    Published 2023-01-01
    Get full text
    Article
  5. 5
    Nuclear p120 catenin is a component of the perichromosomal layer and coordinates sister chromatid segregation during mitosis in lung cancer cells

    Nuclear p120 catenin is a component of the perichromosomal layer and coordinates sister chromatid segregation during mitosis in lung cancer cells by Shu-Er Chow, Yaa-Jyuhn J. Meir, Jhy-Ming Li, Ping-Chih Hsu, Cheng-Ta Yang

    Published 2022-06-01
    Get full text
    Article
  6. 6
    Comparison of Efficacy of 2% Chlorhexidine Gluconate–Alcohol and 10% Povidone-Iodine–Alcohol against Catheter-Related Bloodstream Infections and Bacterial Colonization at Central Venous Catheter Insertion Sites: A Prospective, Single-Center, Open-Label, Crossover Study

    Comparison of Efficacy of 2% Chlorhexidine Gluconate–Alcohol and 10% Povidone-Iodine–Alcohol against Catheter-Related Bloodstream Infections and Bacterial Colonization at Central V... by Ming-Ru Lin, Po-Jui Chang, Ping-Chih Hsu, Chun-Sui Lin, Cheng-Hsun Chiu, Chih-Jung Chen

    Published 2022-04-01
    Get full text
    Article
  7. 7
    Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)

    Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC) by Li-Chung Chiu, Shu-Min Lin, Yu-Lun Lo, Scott Chih-Hsi Kuo, Cheng-Ta Yang, Ping-Chih Hsu

    Published 2021-06-01
    Get full text
    Article
  8. 8
    Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study

    Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study by Chin-Chou Wang, Li-Chung Chiu, Jia-Shiuan Ju, Yu-Ching Lin, Yueh-Fu Fang, Cheng-Ta Yang, Ping-Chih Hsu

    Published 2021-10-01
    Get full text
    Article
  9. 9
    Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

    Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study by Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, John Wen-Cheng Chang

    Published 2021-07-01
    Get full text
    Article
  10. 10
    Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma

    Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma by Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, John Wen-Cheng Chang

    Published 2022-01-01
    Get full text
    Article
  11. 11
    Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations

    Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations by Ping-Chih Hsu, John Wen-Cheng Chang, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Yueh-Fu Fang, Chiao-En Wu

    Published 2022-10-01
    Get full text
    Article
  12. 12
    Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI

    Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI by John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu

    Published 2022-02-01
    Get full text
    Article
  13. 13
    The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer

    The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer by John Wen‐Cheng Chang, Ching‐Fu Chang, Chen‐Yang Huang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Yueh‐Fu Fang, Ping‐Chih Hsu, Chiao‐En Wu

    Published 2023-02-01
    Get full text
    Article
  14. 14
    Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan

    Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan by John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Ping‐Chih Hsu, Chiao‐En Wu

    Published 2023-01-01
    Get full text
    Article
  15. 15
    Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients

    Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients by John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Ping‐Chih Hsu, Chiao‐En Wu

    Published 2022-07-01
    Get full text
    Article
  16. 16
    The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma

    The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma by Ping-Chih Hsu, Chih-Wei Wang, Scott Chih-Hsi Kuo, Shu-Min Lin, Yu-Lun Lo, Allen Chung-Cheng Huang, Li-Chung Chiu, Cheng-Ta Yang

    Published 2020-02-01
    Get full text
    Article
  17. 17
    Blood Cadmium Levels and Oxygen Desaturation during the 6-Minute Walk Test in Patients with Chronic Obstructive Pulmonary Disease

    Blood Cadmium Levels and Oxygen Desaturation during the 6-Minute Walk Test in Patients with Chronic Obstructive Pulmonary Disease by Li-Chung Chiu, Ping-Chih Hsu, Tzung-Hai Yen, Scott Chih-Hsi Kuo, Yueh-Fu Fang, Yu-Lun Lo, Shu-Min Lin, Cheng-Ta Yang, Chung-Shu Lee

    Published 2021-10-01
    Get full text
    Article
  18. 18
    Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients

    Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients by Yan-Jei Tang, John Wen-Cheng Chang, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Yueh-Fu Fang, Ping-Chih Hsu, Chiao-En Wu

    Published 2022-10-01
    Get full text
    Article
  19. 19
    Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer

    Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung c... by Li‐Chung Chiu, Ping‐Chih Hsu, Chin‐Chou Wang, How‐Wen Ko, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Pi‐Hung Tung, Allen Chung‐Cheng Huang, Cheng‐Ta Yang

    Published 2024-03-01
    Get full text
    Article
  20. 20
    Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR‐mutated NSCLC treated with afatinib

    Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR‐mutated NSCLC treated with afatinib by Chen‐Te Wu, Ping‐Chih Hsu, John Wen‐Cheng Chang, Ching‐Fu Chang, Chen‐Yang Huang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Yueh‐Fu Fang, Chiao‐En Wu

    Published 2023-09-01
    Get full text
    Article

Search Tools: